Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Macular Degeneration × aflibercept × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Uveal Melanoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Neurofibromatosis 2 1 Myeloproliferative Disorders 1 Macular Degeneration 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Colorectal Cancer Metastatic 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡